WO2010025400A2 - Cross-reactive and bispecific anti-el 17a/f antibodies - Google Patents
Cross-reactive and bispecific anti-el 17a/f antibodies Download PDFInfo
- Publication number
- WO2010025400A2 WO2010025400A2 PCT/US2009/055420 US2009055420W WO2010025400A2 WO 2010025400 A2 WO2010025400 A2 WO 2010025400A2 US 2009055420 W US2009055420 W US 2009055420W WO 2010025400 A2 WO2010025400 A2 WO 2010025400A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- sequence
- functional fragment
- cdrh2
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 claims abstract description 261
- 108050003558 Interleukin-17 Proteins 0.000 claims abstract description 260
- 239000012634 fragment Substances 0.000 claims description 101
- 230000027455 binding Effects 0.000 claims description 94
- 150000007523 nucleic acids Chemical class 0.000 claims description 92
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 62
- 108091007433 antigens Proteins 0.000 claims description 62
- 102000036639 antigens Human genes 0.000 claims description 62
- 201000010099 disease Diseases 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 54
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 30
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 26
- 230000002757 inflammatory effect Effects 0.000 claims description 25
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 22
- 230000001404 mediated effect Effects 0.000 claims description 22
- 230000008827 biological function Effects 0.000 claims description 21
- 239000000833 heterodimer Substances 0.000 claims description 17
- 208000005252 hepatitis A Diseases 0.000 claims description 12
- 230000000770 proinflammatory effect Effects 0.000 claims description 11
- 241000283984 Rodentia Species 0.000 claims description 9
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 8
- 208000005176 Hepatitis C Diseases 0.000 claims description 8
- 208000005331 Hepatitis D Diseases 0.000 claims description 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 208000002672 hepatitis B Diseases 0.000 claims description 8
- 201000010284 hepatitis E Diseases 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010036105 Polyneuropathy Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 239000000710 homodimer Substances 0.000 claims description 6
- 230000007824 polyneuropathy Effects 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 208000037357 HIV infectious disease Diseases 0.000 claims description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 102220269348 rs61747367 Human genes 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 4
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 206010015218 Erythema multiforme Diseases 0.000 claims description 4
- 208000004332 Evans syndrome Diseases 0.000 claims description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 4
- 206010016946 Food allergy Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000003807 Graves Disease Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 208000037319 Hepatitis infectious Diseases 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 4
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 4
- 206010037075 Protozoal infections Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 208000027207 Whipple disease Diseases 0.000 claims description 4
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000010927 atrophic thyroiditis Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 201000007192 granulomatous hepatitis Diseases 0.000 claims description 4
- 230000001553 hepatotropic effect Effects 0.000 claims description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 230000000366 juvenile effect Effects 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000005987 polymyositis Diseases 0.000 claims description 4
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims description 4
- 201000000306 sarcoidosis Diseases 0.000 claims description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 4
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 4
- 206010043554 thrombocytopenia Diseases 0.000 claims description 4
- 206010043778 thyroiditis Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 description 104
- 102000004196 processed proteins & peptides Human genes 0.000 description 98
- 108090000765 processed proteins & peptides Proteins 0.000 description 98
- 229920001184 polypeptide Polymers 0.000 description 96
- 210000004027 cell Anatomy 0.000 description 75
- 108091028043 Nucleic acid sequence Proteins 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 47
- 102000004169 proteins and genes Human genes 0.000 description 40
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 27
- 125000003729 nucleotide group Chemical group 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 230000000694 effects Effects 0.000 description 24
- 108060003951 Immunoglobulin Proteins 0.000 description 21
- 102000018358 immunoglobulin Human genes 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 17
- 108090000695 Cytokines Proteins 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- 229920001213 Polysorbate 20 Polymers 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 16
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 150000007513 acids Chemical class 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 15
- 108010087819 Fc receptors Proteins 0.000 description 14
- 102000009109 Fc receptors Human genes 0.000 description 14
- -1 ascorbic acid Chemical class 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 102000053162 human IL17A Human genes 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 239000012636 effector Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000004590 computer program Methods 0.000 description 8
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 description 7
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 102000053391 human F Human genes 0.000 description 7
- 108700031895 human F Proteins 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108010073807 IgG Receptors Proteins 0.000 description 6
- 102000009490 IgG Receptors Human genes 0.000 description 6
- 102000004554 Interleukin-17 Receptors Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 102000056946 human IL17F Human genes 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 102220495248 Sodium channel subunit beta-2_C55S_mutation Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102000055008 Matrilin Proteins Human genes 0.000 description 3
- 108010072582 Matrilin Proteins Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000014128 RANK Ligand Human genes 0.000 description 3
- 108010025832 RANK Ligand Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006749 inflammatory damage Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 2
- 102100025698 Cytosolic carboxypeptidase 4 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 2
- 101000932590 Homo sapiens Cytosolic carboxypeptidase 4 Proteins 0.000 description 2
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 102000039989 IL-17 family Human genes 0.000 description 2
- 108091069193 IL-17 family Proteins 0.000 description 2
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 101150108666 LPG3 gene Proteins 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 101001033003 Mus musculus Granzyme F Proteins 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000007977 PBT buffer Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 244000000188 Vaccinium ovalifolium Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- 108091071338 17 family Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108700006072 E coli can Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010014632 NF-kappa B kinase Proteins 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000008421 cartilage matrix synthesis Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates generally to antibodies cross-reactive with IL-17 A and IL-17F, and bispecific anti-IL-17A/F antibodies, and their uses
- Interleukm-17 is a T-cell de ⁇ ved pro-inflammatory molecule that stimulates epithelial, endothelial and fibroblastic cells to produce other inflammatory cytokines and chemokmes including IL- 6, IL-8, G-CSF, and MCP-I [see, Yao, Z et al , J Immunol , 122(12) 5483-5486 (1995), Yao, Z et al, Immunity, 3(6) 81 1 -821 (1995), Fossiez, F , et al , J Exp Med , 183(6) 2593-2603 (1996), Kennedy, J , et al , J Interferon Cytokine Res , 16(8) 61 1 -7 (1996), Cai, X Y , et al , Immunol Lett, 62(1) 51 -8 (1998), Jovanovic, D V , et al , J Immunol , 160(7) 3513-21 (1998), Laan
- IL-17 has further been shown, by intracellular signalling, to stimulate Ca 2+ influx and a reduction m [cAMP], in human macrophages (Jovanovic et al, J Immunol , 160 3513 [1998]) Fibroblasts treated with IL-17 induce the activation of NF- ⁇ B, [Yao et al., Immunity, 3:811 (1995), Jovanovic et al., supra], while macrophages treated with it activate NF- ⁇ B and mitogen-activated protein kinases (Shalom-Barek et al, J. Biol Chem., 273'27467 [1998]).
- IL-17 also shares sequence similarity with mammalian cytokme-like factor 7 that is involved in bone and cartilage growth.
- Other proteins with which IL-17 polypeptides share sequence similarity are human embryo-derived interleukm-related factor (EDIRF) and mterleukin-20.
- IL-17 the cell surface receptor for IL- 17 has been found to be widely expressed in many tissues and cell types (Yao et al., Cytokine, 2:794 [1997]). While the amino acid sequence of the human IL-17 receptor (IL-R) (866 amino acids) predicts a protein with a single transmembrane domain and a long, 525 amino acid intracellular domain, the receptor sequence is unique and is not similar to that of any of the receptors from the cytokme/growth factor receptor family. This coupled with the lack of similarity of IL-17 itself to other known proteins indicates that IL-17 and its receptor may be part of a novel family of signaling proteins and receptors.
- IL-17 receptor the amino acid sequence of the human IL-17 receptor
- IL-17 activity is mediated through binding to its unique cell surface receptor (designated herein as human IL- 17R), wherein previous studies have shown that contacting T cells with a soluble form of the IL- 17 receptor polypeptide inhibited T cell proliferation and IL-2 production induced by PHA, concanavalm A and anti-TCR monoclonal antibody (Yao et al., J. Immunol , 155:5483-5486 [1995]).
- IL- 17 receptor unique cell surface receptor
- IL-17 The large scale sequencing of the human and other vertebrate genomes has revealed the presence of additional genes encoding proteins clearly related to IL-17, thus defining a new family of cytokines.
- IL-17B members of the IL- 17 family in humans and mice including IL-17B, IL-11C, IL- 17D, IL-17E and IL-17F as well as novel receptors IL-17RH1, IL-17RH2, IL-17RH3 and IL-17RH4 (see WO 01/46420 published June 28, 2001).
- IL-17F One such IL-17 member (designated as IL-17F) has been demonstrated to bind to the human IL-17 receptor (IL-17R) (Yao et al., Cytokine, 9(1 1):794-800 (1997)).
- IL-17F The gene encoding human IL-17F is located adjacent to IL-17 (Hymowitz, S G., et al., Embo J, 20(19) 5332-41 (2001)) IL-17 and IL-17F share 44% ammo acid identity whereas the other members of the IL-17 family share a more limited 15-27% amino acid identity suggesting that IL-17 and IL-17F form a distinct subgroup within the IL-17 family (Starnes, T , et al., J Immunol. 167(8):4137-40 (2001 ); Aggarwal, S. and Guraey, A. L., J Leukoc Biol, 71(1) 1-8 (2002)).
- IL-17F appears to have similar biological actions as IL-17, and is able to promote the production of IL-6, IL-8, and G-CSF from a wide variety of cells. Similar to IL-17, it is able to induce cartilage matrix release and inhibit new cartilage matrix synthesis (see U S -2002-0177188-Al published Nov 28, 2002) Thus, like IL-17, IL-17F may potentially contribute to the pathology of inflammatory disorders Recently, these authors have observed that both IL- 17 and IL-17F are induced in T cells by the action of interleukm 23 (IL-23) (Aggarwal, S , et al , J BwI Chem , 278(3) 1910-4 (2003)) The observation that IL- 17 and IL-17F share similar chromosomal localization and significant sequence similarity sd well as the observation that IL-17 and IL- 17F appear to be induced with the same cell population m response to a specific stimuli has lead to the identification of a new human cytokine that is
- IL 17A and IL-17F are now recognized as major proinflammatory cytokines secreted by ThI 7T cell subset They target almost all cell types in body and induce inflammation and tissue damage
- Human IL-17A/F is a distinctly new cytokine, distinguishable from human IL-17 and IL-17F m both protein structure and in cell-based activity assays Through the use of purified recombinant human IL-17A/F as a standard, a human IL-17A/F-specific ELISA has been developed Through the use of this specific ELISA, the induced expression of human IL-17 A/F was detected, confirming that IL-17 A/F is naturally produced from activated human T cells m culture Hence, IL-17A/F is a distinctly new cytokine, detectable as a natural product of isolated activated human T cells, whose recombinant form has been characterized, in both protein structure and cell-based assays, as to be different and distinguishable from related cytokines
- IL-17A/F is disclosed m U S Application Publication Nos 20060270003, published November 30, 2006, and 20070160576, published July 12, 2007 IL-17A/F has been described to as a target for treating various immune-mediated diseases (Chang and Dong, Cell Res 17(5) 435-40 (2007)), an IL-17A/F protein produced by mouse ThI 7 cells has been shown to induce airway neutrophil recruitment and thus having an in vivo function m airway neutrophilia (Liang et al , J Immunol 179(1 1) 7791 -9 (2007)), and the human IL-17A/F heterodime ⁇ c cytokine has been reported to signal through the IL- 17RA/IL- 17RC receptor complex (Wright et al , J Immunol 181 (4) 2799-805 (2008))
- cross-reactive and bispecif ⁇ c antibodies that can block both IL-17A and IL- 17F with high potency
- Such cross-reactive and bispecific antibodies provide new therapeutic opportunities in the treatment of inflammatory and immune-related diseases, including autoimmune diseases, and in the treatment of cancer
- the present invention is based, at least in part, on the production and charactenzation of antibodies cross-reactive with both IL-17A and IL-17F
- the invention further concerns bispecific antibodies binding both to IL- 17A and IL- 17F
- the invention concerns an antibody comprising an antigen-bmdmg domain that binds to IL- 17A and IL-17F and inhibits a biological function of both IL-17 A and IL- 17F, or a functional fragment thereof, where the biological function can, for example, be proinflammatory activity
- the antibody comprises a light chain variable domain comprising CDRLl , CDRL2, and CDRL3 regions, wherein at least one of the CDRLl , CDRL2, and CDRL3 regions is selected from the group consisting of
- CDRLl comprising the sequence DVSTAVA (SEQ ID NO 24) or SISSYLA (SEQ ID NO 25),
- CDRL2 comprising the sequence SASFLYS (SEQ ID NO 26) or GASSRAS (SEQ ID NO 27), and CDRL3 comprising the sequence SYTTPPT (SEQ ID NO 28) or RYSQPIT (SEQ ID NO
- each of the CDRLl , CDRL2, and CDRL3 regions is selected from the group consisting of
- CDRLl comprising the sequence DVSTAVA (SEQ ID NO 24) or SISSYLA (SEQ ID NO 25),
- CDRL2 comprising the sequence SASFLYS (SEQ ID NO 26) or GASSRAS (SEQ ID NO 27), and CDRL3 comprising the sequence SYTTPPT (SEQ ID NO 28) or RYSQPIT (SEQ ID NO
- CDRLl comprises the sequence DVSTAVA (SEQ ID NO 24),
- CDRL2 comprises the sequence SASFLYS (SEQ ID NO 26)
- CDRL3 comprises the sequence SYTTPPT (SEQ ID NO 28)
- CDRLl comprises the sequence SISSYLA (SEQ ID NO 25),
- CDRL2 comprises the sequence GASSRAS (SEQ ID NO 27), and
- CDRL3 comprises the sequence RYSQPIT (SEQ ID NO 29)
- CDRL3 comprises the sequence RYSQPIT (SEQ ID NO 29)
- CDRLl comprises the sequence DVSTAVA (SEQ ID NO 24), and
- CDRL2 comprises the sequence SASFLYS (SEQ ID NO 26, and CDRL3 may comprise the sequence YYIYPAT (SEQ ID NO 31), or a functional fragment thereof
- CDRLl comprises the sequence DVSTAVA (SEQ ID NO 24), and
- CDRL2 comprises the sequence SASFLYS (SEQ ID NO 26), and CDRL3 may comprise the sequence HNDLPLT (SEQ BD NO: 32)
- CDRLl comprises the sequence VISSSLA (SEQ ID NO: 33), and
- CDRL2 comprises the sequence GASFLYS (SEQ ID NO: 34).
- CDRL3 comprises the sequence
- CDRLl comprises the sequence DVSTAVA (SEQ ID NO: 24);
- CDR2 comprises the sequence SASFLYS (SEQ IS NO: 26).
- CDRL3 comprises the sequence
- CDRLl comprises the sequence DVSTAVA (SEQ ID NO: 24);
- CDR2 comprises the sequence SASFLYS (SEQ ID NOT: 26).
- CDRL3 comprises the sequence
- CDRLl comprises the sequence DVSTAVA (SEQ ID NO: 24);
- CDRL2 comprises the sequence SASFLYS (SEQ ID NO: 26).
- CDRL3 comprises the sequence
- CDRLl comprises the sequence RIKRYLA (SEQ ID NO: 89), and
- CDRL2 comprises the sequence GASSRAS (SEQ ID NO: 27).
- CDRL3 comprises the sequence
- CDRLl comprises the sequence SISSYLA (SEQ ID NO: 25), and
- CDRL2 comprises the sequence GASSRAS (SEQ ID NO: 27),
- CDRL3 comprises the sequence
- CDRLl comprises the sequence SISSYLA (SEQ ID NO: 25);
- CDRL2 comprises the sequence GASSRAS (SEQ ID NO: 27).
- the antibody comprises a heavy chain variable domain comprising
- CDRHl, CDRH2, and CDRH3 regions wherein at least one of the CDRHl, CDRH2, and CDRH3 regions is selected from the group consisting of:
- CDRHl comprising a sequence selected from the group consisting of GFTFTD YDIS (SEQ ID NO: 35), GFSFID YDIS (SEQ ID NO: 36), GFSFTSYMMS (SEQ ID NO 81), GFSFPSYFIS (SEQ ID NO: 82); and GFTFYD YDIS (SEQ ID NO. 88),
- CDRH2 comprising a sequence selected from the group consisting of SDGYTYYADSVKG (SEQ ID NO: 37), PDCYTYY ADSVKG (SEQ ID NO 38), PDAYTY PDCYTYYADSVKG (SEQ ID NO: 39), PDSYTTYY ADSVKG (SEQ ID NO 90), YDGYTYYADSVKG (SEQ ID NO- 41), YEGYTYYADSVKG (SEQ ID NO: 44), ESGATDYADSVKG (SEQ ID NO: 83), VSGATVY ADSVKG (SEQ ID NO: 84) YDGYAYYADSVKG (SEQ ID NO: 85); and LDGYSYY ADSVKG (SEQ ID NO: 86), and; and
- CDRH3 comprising a sequence YLYWSYV (SEQ ID NO: 40), and EGYYYSTS ⁇ CYYPW (SEQ ID NO: 87), or a functional fragment thereof.
- the antibody comprises a heavy chain variable domain comprising CDRHl , CDRH2, and CDRH3 regions, wherein each of the CDRHl , CDRH2, and CDRH3 regions is selected from the group consisting of: (a) CDRHl comprising a sequence selected from the group consisting of GFTFTD YDIS
- CDRH2 comprising a sequence selected from the group consisting of SDGYTYYADSVKG (SEQ ID NO- 37), PDCYTYYADSVKG (SEQ ID NO- 38), PDAYTY PDCYTYYADSVKG (SEQ ID NO- 39), PDSYTTYY ADSVKG (SEQ ID NO- 90), YDGYTYYADSVKG (SEQ ID NO' 41), YEGYTYYADSVKG (SEQ ID NO' 44), ESGATDYADSVKG (SEQ ID NO' 83), and VSGATVY ADSVKG (SEQ ID NO: 84), and
- CDRH3 comprising a sequence YLYWSYV (SEQ ID NO 40), or EGYYYSTSIKYYPW (SEQ ID NO 87), or a functional fragment thereof.
- the invention is directed to an antibody which comprises CDRHl , CDRH2 and CDRH3 regions wherein
- CDRLl comprises the sequence DVSTAVA (SEQ ID NO 24),
- CDRL2 comprises the sequence SASFLYS (SEQ ID NO: 26)
- CDRL3 comprises the sequence SYTTPPT (SEQ ID NO: 28)
- CDRHl comprises the sequence GFTFTDYDIS (SEQ ID NO: 35),
- CDRH2 comprises the sequence SDGYTYYADSVKG (SEQ ID NO: 37), and
- CDRH3 comprises the sequence YLYWSYV (SEQ ID NO: 40), or a functional fragment thereof.
- the invention is directed to an antibody which comprises CDRHl ,
- CDRLl comprises the sequence SISSYLA (SEQ ID NO: 25),
- CDRL2 comprises the sequence GASSRAS (SEQ ID NO: 27)
- CDR3 comprises the sequence RYSQPIT (SEQ ID NO: 29)
- CDRHl comprises the sequence GFTFTD YDIS (SEQ ID NO 35),
- CDRH2 comprises the sequence SDGYTYYADSVKG (SEQ ID NO" 37), and
- CDRH3 comprises the sequence YLYWSYV (SEQ ID NO- 40), or a functional fragment thereof.
- the antibody further comprises CDRHl , CDRH2 and CDRH3 regions wherein
- CDRHl comprises the sequence GFSFID YDIS (SEQ ID NO. 36),
- CDRH2 comprises the sequence PDCYTYY ADSVKG (SEQ ID NO 38)
- CDRH3 comprises the sequence YLYWSYV (SEQ ID NO 40).
- the antibody further comprises CDRHl , CDRH2 and CDRH3 regions wherein
- CDRHl comprises the sequence SFSGIDYDIS (SEQ ID NO' 91),
- CDRH2 comprises the sequence YDGYTYY ADSVKG (SEQ ID NO- 41 )
- CDRH3 comprises the sequence YLYWSYV (SEQ ID NO 40).
- the antibody further comp ⁇ ses CDRHl , CDRH2 and CDRH3 regions wherein
- CDRH2 comp ⁇ ses the sequence SDGYTYYADSVKG (SEQ ID NO 37), and (f) CDRH3 comp ⁇ ses the sequence YLYWSYV (SEQ ID NO: 40).
- the antibody further comprises CDRHl , CDRH2 and CDRH3 regions wherein
- CDRH2 comp ⁇ ses the sequence PDAYTYY ADSVKG (SEQ ID NO 42), and (f) CDRH3 comprises the sequence YLYWSYV (SEQ ID NO- 40)
- the antibody further comp ⁇ ses CDRHl , CDRH2 and CDRH3 regions wherem
- CDRHl comprises the sequence GFSFIDYDIS (SEQ ID NO 36),
- CDRH2 comprises the sequence PDSYTYYADSVKG (SEQ DD NO 43)
- CDRH3 comprises the sequence YLYWSYV (SEQ ID NO 40)
- the antibody further comprises CDRHl , CDRH2 and CDRH3 regions wherein
- CDRHl comprises the sequence SFSGIDYDIS (SEQ ID NO: 91),
- CDRH2 comprises the sequence YEGYTYYADSVKG (SEQ ID NO. 44), and (f) CDRH3 comp ⁇ ses the sequence YLYWSYV (SEQ ID NO: 40).
- the antibody binds essentially the same epitope of IL-17 A and IL-17F as a cross-reactive antibody selected from the group consisting of YW241 47, YW278 15, YW279 1 , or an affinity matured variant thereof, or a functional fragment of such antibody or such affinity matured variant.
- the affinity matured variant is selected from the group consisting of antibodies YW278.15.18, YW 178.15.2, YW 278.15.3, YW 278.15.18C55A, YW 278.15.18C55S, and YW 278.15.2.D54E.
- the antibody comprises an antigen-bmdmg domain that binds to IL-17A and IL-17F with substantially the same binding affinity, or a functional fragment thereof
- the antibody comprises an antigen-bmdmg domain that binds to IL- 17A and IL-17F with a binding affinity of at least about 10 l 0 to 10 1 1 M, or a functional fragment thereof.
- the invention concerns an antibody comprising an antigen-bindmg domain that binds to IL-17 A and IL-17F both as a monomer and a homodimer or a heterodimer, or a functional fragment thereof.
- the invention concerns an antibody which binds both human IL-17 A/F and IL-17 A/F of a non-human pnmate, or a functional fragment thereof.
- the non-human primate can, for example, be a Cynomolgus (Cyno) or Rhesus monkey.
- the antibody binds to human IL-17 A/F and optionally a non-human primate IL-17A/F but does not bind a rodent, e.g. rat or mouse, IL-17 A/F.
- the antibody is capable of reducing demyelination in an inflammatory or immune related disease.
- the antibodies of the invention can be monoclonal, and can be chimeric, humanized or human.
- the antibody fragments of the invention include, without limitation, Fab, Fab', F(ab') 2 , and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
- the invention concerns a bispecific antibody comprising a first antigen binding site that binds to IL-17 A and a second antigen binding site that binds to IL-17F, wherein (1 ) the first antigen binding site comprises a first heavy chain variable domain comprising
- CDRHl, CDRH2, and CDRH3 regions wherein at least one of the CDRHl, CDRH2 and CDRH3 regions is selected from the group consitmg of
- CDRH2 comprising the sequence WVGSIYL WGG (SEQ ID NO: 46), and (c) CDRH3 comprising the sequence ARFGQRYA (SEQ ID NO: 47), and
- the second antigen binding site comprises a second heavy chain variable domain comprising CDRHl, CDRH2, and CDRH3 regions, wherein at least one of the CDRHl, CDRH2 and CDRH3 regions is selected from the group consiting of
- CDRHl comprising the sequence TSPYIS (SEQ ID NO: 48)
- CDRH2 comprising the sequence WVASIFYYSG (SEQ BD NO 49)
- CDRH3 comprising the sequence ARGGYGYNQWFYSIYQSY (SEQ ID NO: 50), or an affinity matured variant thereof, or a functional fragment of the antibody or affinity matured variant.
- the bispecific antibody comprises CDRHl, CDRH2, and CDRH3 regions, wherein
- CDRIIl comprises the sequence TSYEIS (SEQ ID NO 45)
- CDRH2 comprises the sequence WVGSIYLWGG (SEQ ID NO 46)
- CDRH3 comprises the sequence ARFGQRYA (SEQ ID NO 47), and
- CDRHl comprises the sequence TSPYIS (SEQ ID NO 48),
- CDRH2 comprises the sequence WV ASIFYYSG (SEQ ID NO 49)
- CDRH3 comprises the sequence ARGGYGYNQWFYSIYQSY (SEQ ID NO 50), or an affinity matured variant thereof, or a functional fragment of the antibody or affinity matured variant
- the bispecific antibody further comprises a light chain vanable domain comprising CDRLl , CDRL2, and CDRL3 regions, wherein at least one of the CDRLl, CDRL2, and CDRL3 regions is selected from the group consisting of
- CDRLl comprising the sequence SISSYLA (SEQ ID NO 25),
- CDRL2 comprising the sequence GASSRAS (SEQ ID NO 27), and
- CDRL3 comprising the sequence YYS SPLT (Residues 91 -97 of SEQ ID NO 21), or an affinity matured variant thereof, or a functional fragment of the antibody or affinity matured variant
- CDRLl comprises the sequence SISSYLA (SEQ ID NO 25),
- CDRL2 comprises the sequence GASSRAS (SEQ ID NO 27)
- CDRL3 comprises the sequence YYSSPLT (Residues 91 -97 of SEQ ID NO 21)
- the bispecific antibody, or functional fragment thereof binds to IL-17A and IL- 17F with substantially the same binding affinity
- the bispecific antibody, or functional fragment thereof binds to IL- 17A and IL- 17F with a binding affinity of at least about 10 10 to 10 ' ' M In an additional embodiment, the bispecific antibody, or functional fragment thereof, binds to IL-
- the bispecific antibody, or functional fragment thereof binds both human and non-human primate IL-17 AfF, wherein the non-human primate may, for example, be a Cynomolgus (Cyno) or Rhesus monkey
- the antibody binds to human IL-17 A/F and optionally a non-human primate IL-17A/F but does not bind a rodent, e g rat or mouse, IL-17A/F
- the bispecific antibody, or functional fragment thereof is capable of reducing demyelmation m an inflammatory or immune related disease
- the bispecific antibody can also be monoclonal, chimeric, humanized or human, and the antibody fragments include, without limitation, Fab, Fab', F(ab') 2 , and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments
- the invention concerns cross-reactive and bispecific antibodies as heremabove described, which inhibit a biological function of IL-17 A m an antibody to IL-17 A molar ratio of about 10 1 to about 1 10, or about 5 1 to about 1 5, or about 1 1 to about 1 5, or about 1 1 to about 1 , or about 1 1 to about 1 2, where IL-17 A stands for an IL- 17A homodimer
- the invention concerns cross-reactive and bispecific antibodies as heremabove described, which inhibit a biological function of IL-17F in an antibody to EL-17F molar ratio of about 10 1 to about 1 10, or about 5 1 to about 1 5, or about 1 1 to about 1 5, or about 1 1 to about 1 3, or about 1 1 to about 1 2, where IL- 17F stands for an IL- 17F homodimer
- the invention concerns cross-reactive and bispecific antibodies as heremabove described, which inhibit a biological function of IL-17 A and IL- 17F in the form of a heterodimer in an antibody to heterodimer molar ratio of about 10 1 to about 1 10, or about 5 1 to about 1 5, or about 1 1 to about 1 5, or about 1 1 to about 1 3, or about 1 1 to about 1 2
- the invention concerns an isolated nucleic acid molecule encoding a light chain of a cross-reactive or bispecific antibody or antibody fragment as heremabove described
- the invention concerns a recombinant host cell comprising a nucleic acid molecule encoding a light chain of a cross-reactive or bispecific antibody or antibody fragment as heremabove described
- the host cell can be eukaryotic or prokaryotic, including, for example, Chinese hamster Ovary (CHO) cells and E coli cells
- the invention further concerns a pharmaceutical composition
- a pharmaceutical composition comprising a cross-reactive or bispecific antibody or antibody fragment as heremabove described in admixture with a pharmaceutically acceptable excipient
- the invention concerns a method for the treatment of an inflammatory or immune related disease comprising administering to a mammalian subject in need an effective amount of a cross- reactive or bispecific antibody of the present invention, or a functional fragment thereof
- the mammalian subject preferably is a human patient
- the inflammatory or immune related condition may, for example, be selected from the group consisting of systemic lupus erythematosis, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis), diabetes mellitus, immune-mediated renal disease (glomerulonephritis, tubulomterstitial nephritis), demy
- the inflammatory or immune related disease is selected from the group consisting of rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and asthma
- the invention concerns an article of manufacture, comprising (a) a container, (b) a label on the container, and (c) a composition of matter comprising a cross-reactive or bispecif ⁇ c antibody of the present invention, contained with the container, wherein the label on said container indicates that the composition of matter can be used for treating an inflammatory or an immune related disease
- the invention further concerns the use of an antibody herein in the preparation of a medicament for the treatment of an inflammatory or an immune related disease
- FIG 1 shows a nucleotide sequence (SEQ ID NO 1) of a native sequence human IL-17A cDNA
- FIG 2 shows the ammo acid sequence (SEQ ID NO 2) derived from the coding sequence of SEQ ID NO 1 shown m
- FIG 1 shows a nucleotide sequence (SEQ ID NO 1) of a native sequence human IL-17A cDNA
- FIG 2 shows the ammo acid sequence (SEQ ID NO 2) derived from the coding sequence of SEQ ID NO 1 shown m
- SEQ ID NO 2 shows the ammo acid sequence (SEQ ID NO 2) derived from the coding sequence of SEQ ID NO 1 shown m
- FIG 1 shows a nucleotide sequence (SEQ ID NO 1) of a native sequence human IL-17A cDNA
- FIG 2 shows the ammo acid sequence (SEQ ID NO 2) derived from the coding sequence of SEQ ID NO 1 shown m
- SEQ ID NO 2 shows the ammo acid sequence (SEQ ID NO 2) derived from the
- FIG 3 shows a nucleotide sequence (SEQ ID NO 3) of a native sequence human IL-17F cDNA
- FIG 4 shows the ammo acid sequence (SEQ ID NO 4) derived from the coding sequence of SEQ
- FIG 5A shows the alignment of light chain sequences of IL-17 A/F cross-reactive antibodies YW 248 65, YW240 27, YW 241 47, YW 271 25, YW 278 15, YW 278 27, YW 278 57, YW 278 60, YW
- FIG 5B shows the alignment of heavy chain sequences of IL-17 A/F cross-reactive antibodies
- FIG 5C shows the alignment of light chain sequences of IL-17A/F cross-reactive antibodies YW
- FIG 5D shows the alignment of heavy chain sequences of IL-17A/F cross-reactive antibodies YW 278 15 7, YW 278 15 8, YW 278 15 9, YW 279 1 20, YW 279 1 21 , and YW 279 1 22 (SEQ ID Nos 69-74)
- FIG 6 shows the alignment of light chain sequences of IL- 17A/F cross-reactive antibody YW278 15 (SEQ ID NO 9) and its affinity matured variants, YW278 15 18 (SEQ ID NO 15),
- FIG 7 shows the alignment of the heavy chain sequences of IL-17A/F cross-reactive antibody YW278 15 (SEQ ID NO 92) and its affinity matured variants, YW278 15 18 (SEQ ID NO 93), YW278 15 2 (SEQ ID NO 94), YW278 15 2 D54E (SEQ ED NO 95), YW278 15 3 (SEQ ID NO 92), YW278 15 18C55A (SEQ ID NO 18) and YW278 15 18C55S (SEQ ID NO 19)
- the CDRLl , CDRL2 and CDRL3 sequences are boxed Note YW278 15 18C55A and YW278 15 18 C55 S have the same light chain as YW278 15 18
- FIGs 8 A and 8B show the results of the BIAcore immunoassay performed with three affinity matured IL-17A/F cross-reactive antibodies
- A The binding affinities to recombinant human IL-17A (rhIL-17A) , recombinant human IL- 17F (rhIL-17F), cyno IL- 17F and human IL-17 A/F m solution (Kd (M)) are shown m the last column B
- the binding affinities to recombinant human IL-17 A (rhIL-17A) , recombinant human IL-17F (rhIL-17F), cyno IL-17F, cyno IL-17A (FIG 8B), and human IL-17A/F m solution (Kd (M)) are shown in the last column
- FIG 9 shows the results of the BIAcore immunoassay performed with two further affinity matured IL-17A/F cross-reactive antibodies, in comparison to YW
- FIG 10 shows the results of the BIAcore immunoassay performed with three affinity matured IL- 17A/F cross-reactive antibodies The binding affinities to rhesus IL-17A are shown in the last column
- FIG 11 shows the alignment of the light chain variable region sequences of IL-17A specific antibody YW264 21 (SEQ ID NO 20) and IL- 17F specific antibody YW265 01 (SEQ ID NO 21)
- FIG 12 shows the alignment of the heavy chain variable region sequences of IL-17A specific antibody YW264 21 (SEQ ID NO 22) and IL-17F specific antibody YW265 01 (SEQ ID NO 23)
- FIGs 13A and 13B show the IC50 and IC90 data foi several IL-17A/F cross-reactive antibodies, as well as the antibody molar ratios needed to inhibit the activity of the target IL-17A/F polypeptides
- FIG 14 shows IL-17 A and IL- 17F binding affinity data for an IL-17A/F bispecific antibody in comparison with anti-IL-17A antibody YW264 1 and anti-IL-17F antibody YW265 01
- FIG 15 shows another alignment of the light chain variable region sequences (SEQ ID NOS 61 and 20-21) of IL-17A/F bispecific antibodies, including antibody YW264 03 (SEQ ID NO 61)
- FIG 16 shows another alignment of the heavy chain variable region sequences (SEQ ID NOS 62 and 22-23) of IL-17A/F bispecific antibodies, including YW264 03 (SEQ ID NO 62)
- FIG 17 shows the Fab bound to an IL-17F dimer
- FIG 18 shows the epitope for Fab on the IL-17F dimer
- IL-17 A/F polypeptide variant means an active IL-17A/F polypeptide as defined above or below having at least about 80% ammo acid sequence identity with a full-length native sequence IL- 17 A/F polypeptide sequence as disclosed herein, an IL- 17 A/F polypeptide sequence lacking the signal peptide as disclosed herein, or any other fragment of a full-length IL-17A/F polypeptide sequence as disclosed herein
- Such IL- 17 A/F polypeptide variants include, for instance, IL- 17 A/F polypeptides wherein one or more ammo acid residues are added, or deleted, at the- or C-terminus of the full-length native ammo acid sequence
- an IL-17A/F polypeptide variant will have at least about 80% ammo acid sequence identity, alternatively at least about 81 % ammo acid sequence identity, alternatively at least about 82% ammo acid sequence identity, alternatively at least about 83% ammo acid sequence identity, alternatively at least about 8
- Percent (%) ammo acid sequence identity with respect to the IL-17A/F polypeptide sequences identified herein is defined as the percentage of ammo acid residues m a candidate sequence that are identical with the ammo acid residues in the specific IL- 17 A/F polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity Alignment for purposes of determining percent ammo acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared For purposes herein, however, % ammo acid sequence identity values are generated using the sequence comparison computer program ALIGN-2 The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc and the source code has
- % ammo acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program
- % ammo acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al , Methods in Enzymology 266 460-480 (1996))
- WU-BLAST-2 is employed, a % amino acid sequence identity value is determined by dividing (a) the number of matching identical ammo acid residues between the ammo acid sequence of the polypeptide of interest having a sequence derived from the native polypeptide and the comparison amino acid sequence of interest (i e , the sequence against which the polypeptide of interest is being
- Percent ammo acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al , Nucleic Acids Res 25 3389-3402 (1997))
- the % ammo acid sequence identity of a given ammo acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a
- IL-17 A/F variant polynucleotides are at least about 30 nucleotides m length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides m length, alternatively at least about 300 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more
- Percent (%) nucleic acid sequence identity with respect to IL-17A/F-encodmg nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides m the IL-17A/F nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity Alignment for purposes of determining percent nucleic acid sequence identity can be achieved m various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megahgn (DNASTAR) software For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program has been filed with user documentation in the U S Copyright Office, Washington D C , 20559, where it is registered under U S Copyright Registration No TXU510087 The ALIGN-2 program is publicly available
- the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows 100 times the fraction W/Z where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 m that program's alignment of C and D, and where Z is the total number of nucleotides m D It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C
- % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program
- % nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al , Methods in Enzymology 266 460-480 (1996))
- a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the IL-17 A/F polypeptide-encodmg nucleic acid molecule of interest having a sequence derived from the native sequence IL-17A/F polypeptid
- Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al , Nucleic Acids Res 25 3389-3402 (1997))
- the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D is calculated as follows 100 times the fraction W/Z where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C
- IL-17A/F variant polynucleotides are nucleic acid molecules that encode an active IL-17A/F polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length IL-17A/F polypeptide as disclosed herein IL-17A/F variant polypeptides may be those that are encoded by an IL-17 A/F variant polynucleotide
- Isolated when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other protemaceous or non-protemaceous solutes
- the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal ammo acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducmg or reducing conditions using Coomassie blue or, preferably, silver stain Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of the IL-17 A/F polypeptide natural environment will not be present Ordinarily, however, isolated polypeptide will be prepared by at least one purification step
- an "isolated" IL- 17 A/F polypeptide-encodmg nucleic acid or other polypeptide-encodmg nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encodmg nucleic acid
- An isolated polypeptide-encodmg nucleic acid molecule is other than m the form or setting in which it is found in nature Isolated polypeptide-encodmg nucleic acid molecules therefore are distinguished from the specific polypeptide-encodmg nucleic acid molecule as it exists in natural cells
- an isolated polypeptide-encodmg nucleic acid molecule includes polypeptide-encodmg nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells
- control sequences refers to DNA sequences necessary for the expression of an operably linked coding sequence m a particular host organism.
- the control sequences that are suitable for prokaryotes include an promoter, optionally an operator sequence, and a ribosome binding site.
- Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
- Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; an promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
- "operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used m accordance with conventional practice.
- “Stringency” of hybridization reactions is readily determmable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
- “Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that. (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50 0 C, (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1 % bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42 0 C; or (3) employ 50% formamide, 5.times SSC (0 75 M NaCl, 0 075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0 1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 ⁇ g/ml), 0.1% SDS, and 10%
- washing solution and hybridization conditions e.g., temperature, ionic strength and % SDS
- An example of moderately stringent conditions is overnight incubation at 37 0 C in a solution comprising 20% formamide, 5X SSC (150 mM NaCl, 15 mM t ⁇ sodmm citrate), 50 mM sodium phosphate (pH 7 6), 5X Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in IX SSC at about 37- 50 0 C
- the skilled artisan will recognize how to adjust the temperature, ionic strength, etc as necessary to accommodate factors such as probe length and the like
- epitope tagged when used herein refers to a chimeric polypeptide comprising an IL- 17A/F polypeptide fused to a "tag polypeptide"
- the tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused
- the tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes
- Suitable tag polypeptides generally have at least six ammo acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues)
- the term "lmmunoadhesm” designates antibody-like molecules which combine the binding specificity of a heterologous protein (an “adhesin”) with the effector functions of immunoglobulin constant domains Structurally, the immunoadhesms comprise a fusion of an ammo acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i e , is "heterologous"), and an immunoglobulin constant domain sequence
- the adhesm part of an lmmunoadhesm molecule typically is a contiguous ammo acid sequence comprising at least the binding site of a receptor or a hgand
- the immunoglobulin constant domain sequence m the lmmunoadhesm may be obtained from any immunoglobulin, such as IgG-I , IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-I and IgA-2), Ig
- antagonist is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native DL-17A/F polypeptide disclosed herein
- agonist is used m the broadest sense and includes any molecule that mimics a biological activity of a native IL-17A/F polypeptide disclosed herein
- Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or ammo acid sequence variants of native IL-17A/F polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc.
- Methods for identifying agonists or antagonists of an IL- 17A/F polypeptide may comp ⁇ se contacting an IL-17A/F polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the IL- 17A/F polypeptide
- Treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented
- “Chronic” administration refers to administration of the agent(s) m a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time
- "Intermittent” administration is treatment that is not consecutively done without interruption, but rather is cyclic m nature
- mammal for purposes of treatment refers to any animal classified as a mammal, including humans, non-human higher primates, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc
- the mammal is human
- Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration m any order
- Carriers as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed Often the physiologically acceptable earner is an aqueous pH buffered solution
- physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids, antioxidants including ascorbic acid, low molecular weight (less than about 10 residues) polypeptide, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagme, argimne or lysine, monosaccharides, disaccha ⁇ des, and other carbohydrates including glucose, mannose, or dext ⁇ ns, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, salt-forming counte ⁇ ons such as sodium, and/or nonionic surfactants such
- antibody is used in the broadest sense and specifically covers, for example, single anti-IL-17A/F or anti-IL17A or anti-IL-17F monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), corresponding antibody compositions with polyepitopic specificity, polyclonal antibodies, single chain antibodies, and antibody fragments (see below) as long as they exhibit the desired biological or immunological activity
- immunoglobulin Ig is used interchangeably with antibody herein
- an “isolated antibody” is one which has been identified and separated and/or recovered from a component of its natural environment Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other protemaceous or nonprotemaceous solutes hi preferred embodiments, the antibody will be purified (1 ) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N- terminal or internal ammo acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain Isolated antibody includes the antibody m situ withm recombinant cells since at least one component of the antibody's natural environment will not be present Ordinarily, however, isolated antibody will be prepared by at least one purification step
- the basic 4-cham antibody unit is a heterotetrame
- immunoglobulins can be assigned to different classes or isotypes There are five classes of immunoglobulins IgA, IgD, IgE, IgG, and IgM, having heavy chains designated ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
- the ⁇ and ⁇ classes are further divided into subclasses on the basis of relatively minor differences in C H sequence and function, e g , humans express the following subclasses IgGl , IgG2, IgG3, IgG4, IgAl , and IgA2
- va ⁇ able refers to the fact that certain segments of the vanable domains differ extensively in sequence among antibodies The V domain mediates antigen binding and define specificity of a particular antibody for its particular antigen However
- hypervariable region when used herein refers to the ammo acid residues of an antibody which are responsible for antigen-bmdmg
- the hypervariable region generally comprises ammo acid residues from a "complementarity determining region" or "CDR" (e g around about residues 24-34 (Ll), 50-56 (L2) and 89-97 (L3) in the V L , and around about 1 -35 (Hl), 50-65 (H2) and 95-102 (H3) in the V H , Kabat et al , Sequences of Proteins of Immunological Interest, 5th Ed Public Health Service, National Institutes of Health, Bethesda, Md (1991)) and/or those residues from a ' hypervariable loop” (e g residues 26-32 (Ll), 50-52 (L2) and 91 -96 (L3) in the V L , and 26-32 (Hl ), 53-55 (H2) and 96-101 (H3) in the V H ,
- the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i e , the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts Monoclonal antibodies are highly specific, being directed against a single antigenic site Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontammated by other antibodies The modifier "monoclonal" is not to be construed as requiring production of the antibody by any particular method For example, the monoclonal antibodies useful m the present invention may be prepared by the hyb ⁇ doma methodology first described by Kohler et al , Nature, 256 495 (1975), or may be made using recombinant DNA methods in bacterial, euk
- the monoclonal antibodies herein include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the cham(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U S Pat No 4,816,567, and Morrison et al , Proc Natl Acad Sci USA, 81 6851-6855 (1984))
- Chimeric antibodies of interest herein include "p ⁇ matized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e g Old World Monkey, Ape etc), and human constant region sequences
- an “intact” antibody is one which comprises an antigen-binding site as well as a C sub L and at least heavy chain constant domains, CHl , CH2 and CH3
- the constant domains may be native sequence constant domains (e g human native sequence constant domains) or ammo acid sequence variant thereof
- the intact antibody has one or more effector functions
- Antibody fragments comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody
- antibody fragments include Fab, Fab', F(ab') 2 , and Fv fragments, diabodies, linear antibodies (see U S Pat No 5,641 ,870, Example 2, Zapata et al , Protein Eng 8(10) 1057-1062 [1995]), single-chain antibody molecules, and multispecific antibodies formed from antibody fragments
- the fragment is "functional," i e qualitatively retains the ability of the corresponding mtact antibody to bind to the target IL-17A and IL-17F polypeptides and, if the mtact antibody also inhibits IL-17A/F biological activity or function, qualitatively retains such inhibitory property as well
- Qualitative retention means that the activity m kind is maintained, but the degree of binding affinity and/or activity might differ
- Papain digestion of antibodies produces two identical antigen-bmdmg fragments, called “Fab” fragments, and a residual "Fc” fragment, a designation reflecting the ability to crystallize readily
- the Fab fragment consists of an entire L chain along with the variable region domain of the H chain (V H ), and the first constant domain of one heavy chain (CHI)
- Each Fab fragment is monovalent with respect to antigen binding, i e , it has a single antigen-bmdmg site
- the Fc fragment comprises the carboxy-termmal portions of both H chains held together by disulfides
- the effector functions of antibodies are determined by sequences in the Fc region, which region is also the part recognized by Fc receptors (FcR) found on certain types of cells
- Fv is the minimum antibody fragment which contains a complete antigen-recognition and - binding site This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association From the folding of these two domains emanate six hyperva ⁇ able loops (3 loops each from the H and L chain) that cont ⁇ bute the ammo acid residues for antigen binding and confer antigen binding specificity to the antibody
- six hyperva ⁇ able loops (3 loops each from the H and L chain) that cont ⁇ bute the ammo acid residues for antigen binding and confer antigen binding specificity to the antibody
- a single variable domain or half of an Fv comprising only three CDRs specific for an antigen
- Single-chain Fv also abbreviated as “sFv” or “scFv” are antibody fragments that comprise the V sub H and V sub L antibody domains connected mto a single polypeptide chain
- the sFv polypeptide further comprises a polypeptide linker between the V sub H and V sub L domains which enables the sFv to form the desired structure for antigen binding
- sFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol 1 13, Rosenburg and Moore eds , Sp ⁇ nger-Verlag, New York, pp 269 315 (1994), Borrebaeck 1995, mfra
- diabodies refers to small antibody fragments prepared by constructing sFv fragments
- humanized forms of non-human (e g , rodent) antibodies are chimeric antibodies that contain minimal sequence derived from the non-human antibody
- humanized antibodies are human immunoglobulins (recipient antibody) m which residues from a hypervanable region of the recipient are replaced by residues from a hypervanable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability
- donor antibody such as mouse, rat, rabbit or non-human primate having the desired antibody specificity, affinity, and capability
- framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues
- humanized antibodies may comprise residues that are not found m the recipient antibody or in the donor antibody These modifications are made to further refine antibody performance
- the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, m which all or substantially all of the hypervanable loops correspond to those of a non-human immunoglobulin and
- cross-reactive antibody is an antibody which recognizes identical or similar epitopes on more than one antigen
- the cross-reactive antibodies of the present invention recognize identical or similar epitopes present on both IL-17A and IL-17F
- the cross-reactive antibody uses the same or essentially the same paratope to bind to both IL- 17A and IL- 17F
- the cross-reactive antibodies herein also block both IL-17A and IL-17F function (activity)
- paratope is used herein to refer to the part of an antibody that binds to a target antigen
- a “species-dependent antibody,” e g , a mammalian anti-IL-17A/F” antibody is an antibody which has a stronger binding affinity for an antigen from a first mammalian species than it has for a homologue of that antigen from a second mammalian species Normally, the species-dependent antibody "bind specifically" to a human antigen (i e , has a binding affinity (Kd) value of no more than about 1 x 10 7 M, preferably no more than about I x IO 8 M and most preferably no more than about 1 x 10 9 M) but has a binding affinity for a homologue of the antigen from a second non-human mammalian species which is at least about 50 fold, or at least about 500 fold, or at least about 1000 fold, weaker than its binding affinity for the human antigen
- the species-dependent antibody can be of any of the various types of antibodies as defined above, but preferably is a humanized or human antibody An antibody "which binds" an antigen of interest, is
- Antibody effector functions refer to those biological activities att ⁇ butable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype
- Examples of antibody effect or functions include CIq binding and complement dependent cytotoxicity, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, down regulation of cell surface receptors (e g , B cell receptor), and B cell activation
- ADCC antibody-dependent cell-mediated cytotoxicity
- FcRs Fc receptors
- cytotoxic cells e g , Natural Killer (NK) cells, neutrophils, and macrophages
- NK cells Natural Killer (NK) cells, neutrophils, and macrophages
- the antibodies “arm” the cytotoxic cells and are absolutely required for such killing
- the primary cells for mediating ADCC, NK cells express Fc gamma RIII only, whereas monocytes express Fc gamma RI, Fc gamma RII and Fc gamma RIII FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kmet, Annu Rev Immunol 9 457-92 (1991)
- an in vitro ADCC assay such as that
- Fc receptor or “FcR” describes a receptor that binds to the Fc region of an antibody
- the preferred FcR is a native sequence human FcR
- a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII subclasses, including allelic variants and alternatively spliced forms of these receptors
- Fc gamma RII receptors include Fc ⁇ RIIA (an "activating receptor”) and Fc ⁇ RIIB (an “inhibiting receptor”), which have similar ammo acid sequences that differ primarily in the cytoplasmic domains thereof
- Activating receptor Fc gamma RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain.
- ITAM immunoreceptor tyrosine-based activation motif
- Inhibiting receptor Fc.gamma.RIIB contains an immunoreceptor tyrosme-based inhibition motif (ITIM) in its cytoplasmic domain (see review M. in Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kmet, Annu. Rev. Immunol. 9:457-492 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al , J. Lab. Clin. Med. 126:330-41 (1995).
- ITIM immunoreceptor tyrosme-based inhibition motif
- FcR neonatal receptor
- FcRn neonatal receptor
- Human effector cells are leukocytes which express one or more FcRs and perform effector functions. Preferably, the cells express at least Fc ⁇ RIII and perform ADCC effector function. Examples of human leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils; with PBMCs and NK cells being preferred.
- PBMC peripheral blood mononuclear cells
- NK natural killer cells
- monocytes cytotoxic T cells and neutrophils
- the effector cells may be isolated from a native source, e g, from blood.
- “Complement dependent cytotoxicity” or “CDC” refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (CIq) to antibodies (of the appropriate subclass) which are bound to their cognate antigen.
- CIq first component of the complement system
- a CDC assay e.g., as described in Gazzano- Santoro et al, Immunol Methods 202: 163 (1996), may be performed.
- label when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a “labeled” antibody.
- the label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable
- solid phase is meant a non-aqueous matrix to which the antibody of the present invention can adhere.
- solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones.
- the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Pat. No. 4,275,149.
- a “liposome” is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as an IL-17A/F polypeptide or antibody thereto) to a mammal.
- a drug such as an IL-17A/F polypeptide or antibody thereto
- the components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
- IL-17A/F polypeptide refers to form(s) of the IL-17A/F polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring IL-17A/F polypeptides
- biological activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring IL-17A/F polypeptide other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring IL-17A/F polypeptide
- an "immunological” activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring IL-17 A/F polypeptide
- One preferred biological activity includes inducing activation of NF- ⁇ B and stimulation of the production of the proinflammatory chemokmes IL-8 and IL-6 Another preferred biological activity includes stimulation of pe ⁇
- anti-IL-17A/F anti-IL-17A or anti-IL-17F
- active or “activity” or “function”, and grammatical variants thereof, are used to refer to the ability to inhibit (blocking or antagonist antibodies) or mimic (agonist antibodies) at least one of the foregoing activities
- antibody fragments referred to as “functional” are characterized by having such properties
- an “immunological” activity refers only to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring IL-17A/F polypeptide
- Degenerative cartilagenous disorder describes a host of disorders that is charactenzed principally by the destruction of the cartilage matrix Additional pathologies includes nitric oxide production, and elevated proteoglycan breakdown Exemplary disorders encompassed withm this definition, include, for example, arthritis (e g , osteoarthritis, rheumatoid arthritis, psoriatic arthritis)
- immune related disease means a disease m which a component of the immune system of a mammal causes, mediates or otherwise contributes to a morbidity m the mammal Also included are diseases m which stimulation or intervention of the immune response has an ameliorative effect on progression of the disease Included withm this term are immune-mediated inflammatory diseases, non- lmmune-mediated inflammatory diseases, infectious diseases, immunodeficiency diseases, neoplasia, etc
- T cell mediated disease means a disease in which T cells directly or indirectly mediate or otherwise contribute to morbidity in a mammal
- the T cell mediated disease may be associated with cell mediated effects, lymphokme mediated effects, etc , and even effects associated with B cells if the B cells are stimulated, for example, by the lymphokmes secreted by T cells
- immune-related and inflammatory diseases examples include systemic lupus erythematosa, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune- mediated thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis), diabetes melhtus, immune-mediated renal disease (glomerulonephritis, tubulomterstiti
- an effective amount is a concentration or amount of an IL-17A/F polypeptide and/or agonist/antagonist which results in achieving a particular stated purpose.
- An "effective amount” of an IL- 17A/F polypeptide or agonist or antagonist thereof may be determined empirically.
- a “therapeutically effective amount” is a concentration or amount of an IL-17A/F polypeptide and/or agonist/antagonist which is effective for achieving a stated therapeutic effect. This amount may also be determined empirically.
- the present invention provides a method for preparing antibodies cross-reactive with IL-17A/F and bispecific antibodies specifically binding to IL-17A and IL-17F.
- IL-17A and IL-17F are major proinflammatory cytokines secreted by ThI 7 T cell subset. They target almost all the cell types in body and induce tissue inflammation and tissue damage. Due to the involvement of these cytokines in inflammation and, in particular, immune related diseases, such as autoimmune diseases, e g. rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), makes it desirable to produce antibodies that are capable of blocking both IL-17A and IL-17F.
- the present invention provides such antibodies. More specifically, the present invention provides antibodies cross-reactive with IL-17 A and IL-17F as well as bispecific antibodies with binding specificities both for IL-17A and IL-17F.
- the antibodies and other recombinant proteins herein can be produced by well known techniques of recombinant DNA technology. Thus, aside from the antibodies specifically identified herein, the skilled practitioner could generate antibodies directed against an antigen of interest, e g., using the techniques described below.
- the antibodies produced in accordance with the present invention are directed against two antigens of interest, IL-17A and IL-17F.
- the IL-17A/F cross-reactive and bispecific antibodies of the present invention have been generated using phage display technology, but other techniques known for making bispecific antibodies and antibodies having an antigen binding region binding to two different antigens can also be used
- an antibody with specificity for one of IL-17 A is diversified such that it develops specificity for IL-17F the while retaining specificity for IL-17A
- an antibody with binding specificity for IL-17F is diversified such that it develops specificity for IL- 17A while retaining specificity for IL- 17F
- this method comprises the steps of (1) diversifying the ammo acid sequence of a light chain variable domain (V L ) of an antibody, wherein prior to the diversification, the antibody comprised a V L and a heavy chain va ⁇ able domain (VH) capable of binding to an epitope on a first IL-17 protein (IL-17A or IL-17F) and (2) selecting a diversified antibody capabl e of binding to the epitope on the first IL- 17 protein (IL- 17 A or IL- 17F) and an epitope on a second IL- 17 protein (IL-17F or IL- 17A)
- V L light chain variable domain
- VH heavy chain va ⁇ able domain
- an antibody that has specificity for two IL-17 polypeptides is isolated from a non-human mammal, such as a mouse or a rat, that was injected with IL-17A and IL- 17F
- bispecificity and/or bivalency has been accomplished by fusing two scFv molecules via flexible linkers, leucine zipper motifs, heterodime ⁇ zation, and by association of scFv molecules to form bivalent monospecific diabodies and related structures
- bispecific antibodies in order to generate bispecific antibodies, one can start with two mono- specific antibodies (e g anti-IL-17A and anti-IL-17F antibodies) The two arms of the antibodies can then be separated and rejoined covalently to form a bispecific antibody
- a bispecific antibody can comprise a common Fc portion and one Fab portion from each of the parental molecules
- one Fab portion is specific for one of the receptor subumts, and the other is specific for a different receptor subumt
- the starting materials need not be intact, bivalent antibodies
- Bispecific antibodies can also be prepared using chemical linkage Brennan et al , Science 229 81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments These fragments are reduced in the presence of the dithiol complexmg agent sodium arsenite to stabilize vicinal dithiols and prevent mtermolecular disulfide formation
- the Fab' fragments generated are then converted to thiomtrobenzoate (TNB) derivatives
- TAB thiomtrobenzoate
- One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody
- Fab'- SH fragments directly recovered from E coli can be chemically coupled vitro to form bispecific antibodies Shalaby et al , J Exp Med 175 217-225 (1992
- Bispecific antibodies include cross-lmked or "heteroconjugate" antibodies
- one of the antibodies in the heteroconjugate can be coupled to avidm
- the other to biotm Heteroconjugate antibodies may be made using any convenient cross-linking methods Suitable cross-linking agents are well known in the art, and are disclosed m U S Pat No 4,676,980, along with a number of cross-linking techniques
- Bispecific antibodies have also been produced using leucine zippers Kostelny et al , J Immunol 148(5) 1547-1553 (1992)
- the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion
- the antibody homodimers were reduced at the hmge region to form monomers and then re-oxidized to form the antibody heterodimers
- This method can also be utilized for the production of antibody homodimers
- the "diabody" technology described by Hollmger et al , Proc Natl Acad Sa USA 90 6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments
- the fragments comprise a heavy-chain variable domain (V H ) connected to a light-cham variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary V L and V
- recombinant techniques can be used to generate a smgle-chain bispecific antibody, as described, for example, m Whitlow et al (1991), Methods A Companion to Methods m Enzymology, VoI 2, page 97, Bird et al (1988), Science 242, 423-426, U S Pat No 4,946,778, Pack et al (1993), Bio/Technology 11 , 1271 -77, and Sandhu (1992), Crit Rev Biotech 12, 437 Methods for generating bispecific single chain antibodies, m particular, are described, e g , m U S Pat No 5,892,020, Gruber et al (1994) J Immunol 152, 5368-74, Mallender et al (1994) Biochemistry 33, 10100-10108, Winter et al (1991) Nature 349, 293-299, Schmidt et al (1996) International Journal of Cancer 65, 538-546, and Thi ⁇ on et al (1996) Eur J of Cancer Prevention 5, 507
- the nucleic acid encoding it may be isolated and inserted into a replicable vector for further cloning (amplification of the DNA) or for expression
- the antibody may be produced by homologous recombination, e g as described in U S Pat No 5,204,244, specifically incorporated herein by reference
- DNA encoding the monoclonal antibody is readily isolated and sequenced using conventional procedures (e g , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody)
- Many vectors are available
- the vector components generally include, but are not limited to, one or more of the following a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence, e g , as desc ⁇ bed m U S Pat No 5,534,615 issued JuI 9, 1996 and specifically incorporated herein by reference
- Suitable host cells for cloning or expressing the DNA encoding antibody chains include mammalian host cells Interest has been great in mammalian host cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure
- useful mammalian host cell lines are monkey kidney CVl line transformed by SV40 (COS-7, ATCC CRL 1651), human embryonic kidney line (293 or 293 cells subcloned for growth m suspension culture, Graham et al , J Gen Virol 36 59 (1977)), baby hamster kidney cells (BHK, ATCC CCL 10), Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al , Proc Natl Acad Sci USA 77 4216 (1980)), mouse Sertoli cells (TM4, Mather, Biol Reprod 23 243-251 (1980)), monkey kidney cells (CVl ATCC CCL 70), African green monkey kidney cells (VERO-76, ATCC CRL-1587), human cervical carcinoma cells (HELA, ATCC CCL 2)
- the mammalian host cells may be cultured m a va ⁇ ety of media
- Commercially available media such as Ham's FlO (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI- 1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for cultunng the host cells
- any of the media described m Ham et al , Meth Enz 58 44 (1979), Barnes et al , Anal Biochem 102 255 (1980), U S Pat Nos 4,767,704, 4,657,866, 4,927,762, 4,560,655, or 5,122,469, WO 90/03430, WO 87/00195, or U S Pat Re 30,985 may be used as culture media for the host cells Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chlo ⁇
- the antibody composition prepared from the cells can be pu ⁇ fied using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, with affinity chromatography being the preferred purification technique
- affinity chromatography being the preferred purification technique
- the suitability of protein A as an affinity hgand depends on the species and isotype of any immunoglobulin Fc domain that is present m the antibody Protein A can be used to pu ⁇ fy antibodies that are based on human ⁇ l , human ⁇ 2, or human ⁇ 4 heavy chains (Lmdmark et al , J Immunol Meth 62 1 -13 (1983)) Protein G is recommended for all mouse isotypes and for human ⁇ 3 (Guss et al , EMBO J 5 15671575 (1986))
- the matnx to which the affinity hgand is attached is most often agarose, but other matrices are available Mechanically stable matrices such as controlled pore glass or poly(s
- a humanized antibody has one or more ammo acid residues introduced into it from a source which is non-human These non-human ammo acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain Humamzation can be essentially performed following the method of Winter and co-workers (Jones et al , Nature, 321 522-525 (1986), Riechmann et al , Nature, 332 323-327 (1988), Verhoeyen et al , Science, 239 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody Accordingly, such "humanized” antibodies are chimeric antibodies (U S Patent No 4,816,567) wherein substantially less than an mtact human variable domain has been substituted by the corresponding sequence from a non-human species In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analog
- variable domains both light and heavy
- sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences
- the human sequence which is closest to that of the rodent is then accepted as the human FR for the humanized antibody
- Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains The same framework may be used for several different humanized antibodies (Carter et al Proc Natl Acad Sa USA, 89 4285 (1992), Presta et al , J lmmnol , 151 2623 (1993))
- humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences
- Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art
- Computer programs are available which illustrate and display probable three- dimensional conformational structures of selected candidate immunoglobulin sequences Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i e , the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen
- FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved
- the CDR residues are directly and most substantially involved in influencing antigen binding
- transgenic animals e g , mice
- transgenic animals e g , mice
- J H antibody heavy -chain joining region
- the antibodies of the present invention are useful in the treatment of inflammatory and immune related diseases associated with the production of IL-17A and/or IL-17F
- the cross-reactive and bispecific antibodies that can block both IL- 17A and IL- 17F with high potency provide new therapeutic opportunities in the treatment of inflammatory and immune-related diseases, including autoimmune diseases
- Examplary inflammatory and immune-related diseases targeted by the cross-reactive and bispecific antibodies of the present invention include systemic lupus erythematosa, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis (scleroderma), idiopathic inflammatory myopathies (dermatomyositis, polymyositis), Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia (immune pancytopenia, paroxysmal nocturnal hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia), thyroiditis (Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis), diabetes melhtus, immune-mediated renal disease
- the antibody or antibody fragment compositions herein will be formulated, dosed, and administered m a fashion consistent with good medical practice Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners
- the "therapeutically effective amount" of the antibody or antibody fragment to be administered will be governed by such considerations, and is the minimum amount necessary to prevent, ameliorate, or treat a target disease, such as any of the diseases and conditions listed above
- the antibody or antibody fragment need not be, but is optionally formulated with one or more agents currently used to prevent or treat the target disease
- the effective amount of such other agents depends on the amount of antibody or antibody fragment present in the formulation, the type of disorder or treatment, and other factors discussed above These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages
- treatment of a target disease involves the lessening of one or more symptoms or medical problems associated with the the target disease
- the target disease is an inflammatory disease or condition
- the treatment can reduce inflammation and/or alleviate one or more symptoms associated with inflammation
- the cross-reactive and bispecific anti-ILl 7A/F antibodies of the present invention can prevent, reduce, or slow down the physical manufestations of the target disease
- the treatment may prevent, lessen, reduce, or slow down the development ofstructural damage, such as bone erosions and joint damage characte ⁇ stic of the disease
- the cross-reactive and bispecific antibodies of the present invention can be combined with other treatment modalities used in clinical practice, such as administration of Rituxan ® ( ⁇ tuximab), alone or m combination with methotrexate, to treat patients with moderately-to- severely active rheumatoid arthritis (RA)
- Other treatment options that can be used in combination with the antibodies of the present invention include
- the treatment may prevent, lessen, reduce, or slow down the development of inflammation, and/or one or more of the accompanying symptoms, including abdominal pam, diarrhea or constipation, fatigue, and fever
- IBD inflammatory bowel disease
- Treatment with the cross-reactive and bispecific antibodies of the present invention can be combined with traditional treatments for the management of IBD, including aminosalicylates, corticosteroids, antibiotics, and other biologic treatment options, such as TNF antagonist therapies, such as etanercept, infliximab, or adalimumab
- Therapeutic formulations are prepared using standard methods known m the art by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences (20 sup th edition), ed A Gennaro, 2000, Lippmcott, Williams & Wilkms, Philadelphia, Pa ) Acceptable earners, include salme, or buffers such as phosphate, citrate and other organic acids, antioxidants including ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, such as serum albumin, gelatin or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, ammo acids such as glycine, glutamme, asparagmes, arginme or lysine, monosaccharides, disaccha ⁇ des, and other carbohydrates including glucose, mannose, or dext ⁇ ns, chelating agents such as EDTA, sugar alcohols such as manmtol or sorbitol, salt-
- the formulation contains a pharmaceutically acceptable salt, preferably sodium chloride, and preferably at about physiological concentrations
- the formulations of the invention can contain a pharmaceutically acceptable preservative
- the preservative concentration ranges from 0 1 to 2 0%, typically v/v Suitable preservatives include those known in the pharmaceutical arts Benzyl alcohol, phenol, m-cresol, methylparaben, and propylparaben are preferred preservatives
- the formulations of the invention can include a pharmaceutically acceptable surfactant at a concentration of 0 005 to 0 02%
- the formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other Such molecules are suitably present in combination in amounts that are effective for the purpose intended
- the active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by mterfacial polymerization, for example, hydroxymethylcellulose or ge
- Sustamed-release preparations may be prepared Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matnces are in the form of shaped articles, e g , films, or microcapsule
- sustamed- release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vmylalcohol)), polylactides (U S Pat No 3,773,919), copolymers of L-glutamic acid and gamma ethyl-L-glutamate, non-degradable ethyl ene-vmyl acetate, degradable lactic acid-glycohc acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybuty ⁇ c acid While polymers such as
- the antibodies and antibody fragments described herein are administered to a human subject, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, mtracerobrospmal, subcutaneous, mtra-articular, mtrasynovial, intrathecal, oral, topical, or inhalation routes Local administration may be particularly desired if extensive side effects or toxicity is associated with the antibodies herein antagonism
- An ex vivo strategy can also be used for therapeutic applications
- Ex vivo strategies involve transfectmg or transducing cells obtained from the subject with a polynucleotide encoding an antibody or antibody fragment The transfected or transduced cells are then returned to the subject
- the cells can be any of a wide range of types including, without limitation, hemopoietic cells (e g , bone marrow cells, macrophages, monocytes, dendritic cells, T cells, or B cells), fibro
- Another embodiment of the invention is an article of manufacture containing materials useful for the treatment of diseases or conditions targeted by the antibodies of the present invention
- the article of manufacture comprises a container and a label or package insert on or associated with the container
- Suitable containers include, for example, bottles, vials, syringes, etc.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- At least one active agent m the composition is a cross-reactive or bispecific antibody or antibody fragment antibody of the invention.
- the label or package insert indicates that the composition is used for treating the particular condition.
- the label or package insert will further comprise instructions for administering the antibody composition to the patient Articles of manufacture and kits comprising combinatorial therapies described herein are also contemplated.
- Package insert refers to instructions customarily included in commercial packages of therapeutic products that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.
- the package insert indicates that the composition is used for treating of an inflammatory or immune related condition, such as, for example, any of the conditions listed before, including various forms of arthritis, e g. rheumatoid arthritis, inflammatory bowel disease (IBD), other autoimmune diseases, or allegic conditions, such as asthma.
- IBD inflammatory bowel disease
- the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate- buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
- a pharmaceutically-acceptable buffer such as bacteriostatic water for injection (BWFI), phosphate- buffered saline, Ringer's solution and dextrose solution.
- phage libraries were sorted four rounds against either IL-17 A or IL-17 F alone
- phage libraries were sorted against IL-17A and IL-17 F interchangeably m alternative rounds
- Nunc 96 well Maxisorp immunoplates were coated overnight at 4 0 C with target antigen (lO ⁇ g/ml) and were blocked for 1 hour at room temperature with phage blocking buffer PBST (phosphate-buffered salme (PBS) and 1 % (w/v) bovme serum albumin (BSA) and 0 05% (v/v) tween-20)
- PBST phosphate-buffered salme
- BSA bovme serum albumin
- affinities of phage antibodies were ranked using spot competition ELISA
- the phage antibody IC50 values were further determined using competitive phage-bmding ELISA
- Unique phage antibodies that bind both human IL-17 A and IL-17 F with highest IC50 were chosen and reformatted to full length IgGs for evaluation in in vitro cell assay
- Clones of interest were reformatted into IgGs by cloning V L and V H regions of individual clones into the LPG3 and LPG4 vector respectively, transiently expressing in mammalian CHO cells, and purifying with a protein A column
- Human neonatal foreskin fibroblasts (Invitrogen) were seeded in 96-well plate at 2x104 cells/ 150 ⁇ l media/well on day 1 Media was replaced with cytokme/antibody containing media (150 ⁇ l) on day 2 Recombinant human IL-17A was used at 5 ng/ml Recombinant human IL-17F was used at 50 ng/ml Recombinant human Ih-I lAJf heterodimer was purified m-house and was used at 25 ng/ml Supernatant was harvested 24 hours later and G-CSF ELISA was performed to measure G-CSF induction Data was plotted in PRISM and IC50/90 values calculated using the same software
- phage libraries were subjected to plate sorting for the first round, followed by four or five rounds of solution sorting
- the libraries were sorted individually against human IL- 17 A and IL- 17 F, separately
- the libraries were sorted against target coated plate (NUNC Maxisorp plate) with phage input about 3 O D /ml in 1 % BSA and 0 05% Tween 20 for 2 hours at room temperature
- solution sorting was performed to increase the stringency of selection
- 1 O D /ml phage propagated from the first round of plate sorting were incubated with 100 nM biotmylated target protein (the concentration is based on parental clone phage IC50 value) m lOO ⁇ l buffer containing 1% Superblock (Pierce Biotechnology) and 0 05% Tween20 for 30 minutes at room temperature
- the mixture was further diluted 1 OX with 1% Superblock, and lOO ⁇ l
- Colonies were picked fiom the fifth or sixth round screens Colonies were grown overnight at 37°C in 150 ⁇ l/well of 2YT media with 50 ⁇ g/ml carbemcillm and lElO/ml KO7 in 96-well plate (Falcon) From the same plate, a colony of XL-I infected parental phage was picked as control 96-well Nunc Maxisorp plates were coated with lOO ⁇ l/well of human IL- 17 A and IL- 17 F (2 ⁇ g/ml) separately in PBS at 4°C overnight or room temperature for 2 hours The plates were blocked with 65 ⁇ l of 1 % BSA for 30 mm and 40 ⁇ l of 1 % Tween 20 for another 30 minutes
- the phage supernatant was diluted 1 10 in ELISA (enzyme linked immunosorbent assay) buffer (PBS with 0 5% BSA, 0 05% Tween20) with or without 1OnM target protein m lOO ⁇ l total volume and incubated at least 1 hour at room temperature m an F plate (NUNC) 75 ⁇ l of mixture with or without target protein was transferred side by side to the target protein coated plates The plate was gently shaken for 15 mm to allow the capture of unbound phage to the target protem-coated plate The plate was washed at least five times with PBS-O 05% Tween 20 The binding was quantified by adding horseradish peroxidase (HRP)-conjugated anti-M13 antibody in ELISA buffer (1 5000) and incubated for 30 minutes at room temperature The plates were washed with PBS-O 05% Tween 20 at least five times Next, lOO ⁇ l/well of a 1 1 ratio of 3,3',5,5'-t
- Binding affinities of anti IL- 17 A/F IgGs were measured by Surface Plasmon Resonance (SRP) using a BIAcoreTM-3000 instrument
- Anti IL-17 A/F human IgG was captured by mouse anti-human Fc antibody (GE Healthcare, cat# BR-1008-39) coated on CM5 biosensor chips to achieve approximately 200 response units (RU)
- SRP Surface Plasmon Resonance
- two-fold serial dilutions (0 98nM to 125nM) of human IL-17A (R&D Systems, cat# 317-IL-050/CF), IL-17 F (R&D, cat# 1335-IL-025/CF), IL-17A/F (GNE), Rhesus IL-17F (GNE), Cyno IL-17A (PURl 7200) were injected in PBT buffer (PBS with 0 05% Tween 20) at 25°C with a flow rate of 30 ⁇ l/min Association rates (k on )
- IL-17A & IL17-F are major pro-inflammatory cytokines secreted by Thl7 T cell subset They target almost all the cell types in body and induce tissue inflammation and tissue damage
- the goal of the work described in the present example has been to generate cross-reactive antibodies that can block both IL-17A & F with high potency and cross-species reactivity
- the light chain va ⁇ able region sequences of cross-reactive anti-IL-17A/F clones are shown m Figure 5A (SEQ ID NOs 5-14), including the CDRLl , CDRL2, and CDRL3 sequences
- the heavy chain variable region sequence of cross-reactive anti-IL-17A/F clones are shown in Figure 5B (SEQ ID NOs 51 -60)
- YW241 47, YW278 15 and YW279 1 showed particularly strong binding to both IL-17A and IL-17F, both in monodime ⁇ c and heterodime ⁇ c form
- cross-reactive antibodies YW278 15 and 279 1 show nearly equal blocking of IL-17A and F Of these, cross-reactive antibody YW278 15 was selected for affinity maturation
- Heavy chain va ⁇ able region sequences of further cross-reactive anti-A/F antibodies including affinity matured variants of YW278 15 and YW279 1 , are shown m Figure 5D (SEQ ID Nos 69-74)
- FIG 6 shows the alignment of light chain sequences of IL-17A/F cross-reactive antibody YW278 15 (SEQ ID NO 9) and its affinity matured variants, YW278 15 18 (SEQ ID NO 15), YW278 15 2 (SEQ ID NO 16), and YW278 15 3 (SEQ BD NO 17)
- the CDRLl , CDRL2 and CDRL3 sequences are boxed
- FIG 7 shows the alignment of the heavy chain sequences of IL-17A/F cross-reactive antibody YW278 15 (SEQ ID NO 92) and its affinity matured variants, YW278 15 18 (SEQ ID NO 93), YW278 15 2 (SEQ ED NO 94), 278 15 2 D54E (SEQ ID NO 95), YW278 15 3 (SEQ ID NO 92), YW278 15 18C55A (SEQ ID NO 18) and YW278 15 18C55S (SEQ ID NO 19)
- the CDRLl , CDRL2 and CDRL3 sequences are boxed YW278 15 18C55A and YW278 15 18C55S have the same light chain as YW278 15 18, and the C55A and C55S mutations in the antibody heavy chains were introduced to facilitate manufactunng
- FIG 8A shows the results of the BIAcoreTM immunoassay performed with three affinity matured IL-17A/F cross-reactive antibodies, YW278 15 2, YW278 15 18, and YW278 15 3
- the binding affinities to recombinant human IL- 17A (rhIL-17A), recombinant human IL- 17F (rhIL-17F), cyno IL- 17F and human IL-17 A/F m solution (Kd (M)) are shown m the last column
- FIG 8B shows the results of the BIAcoreTM immunoassay performed with affinity matured IL- 17A/F cross-reactive antibodies, YW278 15 2 D54E, YW278 15 3, YW278 15 9, YW279 1 20, YW279 1 21 , YW279 1 22
- FIG 9 shows the results of the BIAcoreTM immunoassay performed with two further affinity matured IL-17A/F cross-reactive antibodies, YW278 15 18 C55A and YW278 15 18 C55S, in comparison to YW278 15 18
- the binding affinities to recombinant human IL-17 A (rhIL-17A) , recombinant human IL-17F (rhIL-17F), cyno IL-17F, and human IL-17A/F in solution (Kd (M)) are shown in the last column
- FIG 10 shows the results of the BIAcoreTM immunoassay performed with three affinity matured IL-17 A/F cross-reactive antibodies, using rhesus IL-17A as the target The binding affinities to rhesus IL- 17A are shown in the last column
- FIGs 13A and 13B show IC50 and IC90 data for a set of cross-reactive antibodies, as determined in repeated assays The antibody to target cytokine molar ratios are also shown
- LPG3 and LPG4 vectors respectively, transiently expressing in mammalian CHO cells, and purifying with a protein A column
- Bi-specific antibody one arm of the antibody specific for IL-17A and the other specific for IL-17F
- knob-and-hole technology see Merchant et al , Nature Biotechnology, 16 677-681, 1998 and Atwell S et al , JMoI Biol 270(1) 2635 (1997)
- Binding affinities of anti IL- 17 A/F IgGs were measured by Surface Plasmon Resonance (SRP) using a BIAcoreTM-3000 instrument
- Anti IL-17 A/F human IgG was captured by mouse anti-human Fc antibody (GE Healthcare, cat# BR-1008-39) coated on CM5 biosensor chips to achieve approximately 200 response units (RU)
- SRP Surface Plasmon Resonance
- two-fold serial dilutions (0 245nM to 50OnM) of human IL-17A (R&D Systems, cat# 317-IL-050/CF) or IL-17 F (R&D, cat# 1335-IL-025/CF) were injected in PBT buffer (PBS with 0 05% Tween 20) at 25°C with a flow rate of 30 ⁇ l/rmn Association rates (Ar 0n ) and dissociation rates (k o a) were calculated using a simple one-to-one Langmuir binding model (
- FIG. 11 shows the alignment of the light chain variable region sequences of IL-17 A specific antibody YW264.21 (SEQ ID NO: 20) and IL-17F specific antibody YW265.01 (SEQ ID NO: 21).
- FIG. 12 shows the alignment of the heavy chain variable region sequences of IL-17A specific antibody YW264 21 (SEQ ID NO: 22) and IL-17F specific antibody YW265.01 (SEQ ID NO: 23).
- FIG. 14 shows IL-17 A and IL- 17F binding affinity data for an IL-17 A/F bispecific antibody in comparison with anti-IL-17A antibody YW264.21 and anti-IL-17F antibody YW265.01.
- FIG. 15 shows the alignment of the light chain variable region sequences of IL-17A specific antibodies YW264.21 (SEQ ID NO: 20) and YW264.03 (SEQ ID NO: 61) and IL-17F specific antibody YW265.01 (SEQ ID NO: 21).
- FIG. 16 shows the alignment of the heavy chain variable region sequences of IL-17A specific antibodies YW26421 (SEQ ID NO: 22) and YW264.03 (SEQ ID NO: 62) and IL-17F specific antibody YW265.01 (SEQ ID NO: 23).
- IL-17F was expressed and purified as described in Hymowitz SG, et al., EMBO J., 2001, 20:5332-5341. Briefly, DNA encoding 1L-17F was subcloned into pET15b (Novagen) sites in order to introduce an N-terminal His-tag and thrombin cleavage site.
- the coding region was subcloned into the baculovirus transfer vector pAcGP67B (PharMingen), which was then co- transfected with BaculoGold DNA (PharMingen) into Sf9 cells, and recombinant virus was isolated and amplified in Sf9 cells
- Hi5 cells were infected with amplified baculovirus.
- the medium was harvested by centrifugation and the pH was adjusted to 7 0.
- the medium was filtered and loaded onto a Ni-NTA column. Fractions containing IL-17F were eluted with imidazole, pooled and dialyzed into PBS, pH 6.5, together with thrombin overnight at 4 "C.
- the protein sample was then concentrated and the thrombin and His-tag were removed by purification over a size exclusion column.
- the Fab fragment of YW 278.15.18.C55S (hereafter referred to as "fab") was expressed in E coh, pu ⁇ fied using Protein G-Sepharose, and eluted with 0.58% acetic acid. Fab-containing fractions were then purified using a SP HiTrap column (GE Healthcare) with 2OmM MES pH 5.5 and a NaCl gradient. Final buffer was 25mM T ⁇ s, 100 mM NaCl, pH7.5.
- the IL-17F- fab complex was crystallized using vapor diffusion using hanging drops
- the hanging drop was set up by mixing 2 ul of protein and 2 ul of well solution (40% MPD, 5% PEG 8000, and 0 1 M Na Cacodylate pH6 5) at 19 0 C Crystals grew after 5 days incubation, and were washed and frozen directly in mother liquid in liquid nitrogen
- Crystallographic data was collected beamlme 1 1 -1 at the Stanford Synchtron Radiation Laboratory
- the data sets were processed using the programs in the HKL package (HKL, Charlottesville, VA)
- the structure was solved by molecular replacement using the program PHASER (CCP4) using a variant of the humanized 4D5 Fab (PDB code 1 FVE) as the search model followed by refinement with REFMAC5 (CCP4)
- PHASER program 4H4
- PDB code 1 FVE humanized 4D5 Fab
- REFMAC5 CCP4
- the final model has excellent geometry with 99 6% of all residues in the most favored or additional allowed regions of a Ramachandran plot and only 0 6 % (6 residues) in either the generously allowed or disallowed regions
- FIG. 17 shows the Fab bound to an IL-17F dimer
- FIG. 18 shows the epitope for Fab on the IL-17F dimer.
- the epitope is centered on a cysteine knot, and is largely conserved between Ll 7A and ILl 7F (residues in parenthesis are sequence differences between F and A).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801338455A CN102137872A (en) | 2008-08-29 | 2009-08-28 | Cross-reactive and bispecific anti-IL 17A/F antibodies |
BRPI0916915A BRPI0916915A2 (en) | 2008-08-29 | 2009-08-28 | bispecific cross-reactive anti-il-17a / f antibodies |
EP09792076A EP2321349A2 (en) | 2008-08-29 | 2009-08-28 | Cross-reactive and bispecific anti-el 17a/f antibodies |
JP2011525247A JP2012501186A (en) | 2008-08-29 | 2009-08-28 | Cross-reactive and bispecific anti-IL-17A / F antibodies |
MX2011002073A MX337684B (en) | 2008-08-29 | 2009-08-28 | Cross-reactive and bispecific anti-el 17a/f antibodies. |
CA2732642A CA2732642A1 (en) | 2008-08-29 | 2009-08-28 | Cross-reactive and bispecific anti-il-17a/f antibodies |
AU2009285616A AU2009285616B2 (en) | 2008-08-29 | 2009-08-28 | Cross-reactive and bispecific anti-IL 17A/F antibodies |
ZA2011/00749A ZA201100749B (en) | 2008-08-29 | 2011-01-28 | Cross-reactive and bispecific anti-il 17a/f antibodies |
IL210942A IL210942A0 (en) | 2008-08-29 | 2011-01-30 | Cross-reactive and bispecific anti-il 17a/f antibodies |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9321208P | 2008-08-29 | 2008-08-29 | |
US61/093,212 | 2008-08-29 | ||
US11264408P | 2008-11-07 | 2008-11-07 | |
US61/112,644 | 2008-11-07 | ||
US16470909P | 2009-03-30 | 2009-03-30 | |
US61/164,709 | 2009-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010025400A2 true WO2010025400A2 (en) | 2010-03-04 |
WO2010025400A3 WO2010025400A3 (en) | 2010-07-15 |
Family
ID=41497126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/055420 WO2010025400A2 (en) | 2008-08-29 | 2009-08-28 | Cross-reactive and bispecific anti-el 17a/f antibodies |
Country Status (17)
Country | Link |
---|---|
US (2) | US8790642B2 (en) |
EP (2) | EP2321349A2 (en) |
JP (1) | JP2012501186A (en) |
KR (1) | KR20110055692A (en) |
CN (2) | CN103360493A (en) |
AR (1) | AR073232A1 (en) |
AU (2) | AU2009285616B2 (en) |
BR (1) | BRPI0916915A2 (en) |
CA (1) | CA2732642A1 (en) |
CL (1) | CL2011000397A1 (en) |
IL (1) | IL210942A0 (en) |
MX (1) | MX337684B (en) |
PE (1) | PE20110801A1 (en) |
SG (1) | SG10201507009YA (en) |
TW (1) | TW201012478A (en) |
WO (1) | WO2010025400A2 (en) |
ZA (1) | ZA201100749B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012093254A1 (en) | 2011-01-07 | 2012-07-12 | Ucb Pharma S.A. | Lipocalin 2 as a biomarker for il-17 inhibitor therapy efficacy |
WO2012095662A1 (en) | 2011-01-14 | 2012-07-19 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
WO2012156219A1 (en) * | 2011-05-05 | 2012-11-22 | Ablynx Nv | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
EP1641822B1 (en) * | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
WO2016070062A3 (en) * | 2014-10-31 | 2016-08-18 | Genentech, Inc. | Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same |
US9475873B2 (en) | 2009-05-05 | 2016-10-25 | Novimmune Sa | Nucleic acids encoding anti-IL-17F antibodies and methods of use thereof |
WO2017072183A1 (en) * | 2015-10-27 | 2017-05-04 | Ucb Biopharma Sprl | Methods of treatment using anti-il-17a/f antibodies |
US9650437B2 (en) | 2008-05-05 | 2017-05-16 | Novimmune S.A. | Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies |
US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
US10208113B2 (en) | 2014-06-23 | 2019-02-19 | Janssen Biotech, Inc. | Interferon α and ω antibody antagonists |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
EP3176184B1 (en) | 2010-11-10 | 2020-02-19 | F. Hoffmann-La Roche AG | Anti-bace1 antibodies for neural disease immunotherapy |
CN103308697B (en) * | 2013-06-09 | 2014-11-26 | 卫生部北京医院 | Kit used for detecting natural bispecific antibody resistant to HCV (hepatitis C virus) coded non-structural proteins NS3 and NS5 |
NZ756749A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
EP4163633A1 (en) | 2013-09-13 | 2023-04-12 | F. Hoffmann-La Roche AG | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
CN103554264B (en) * | 2013-11-05 | 2015-08-12 | 哈尔滨博翱生物医药技术开发有限公司 | For bi-specific antibody and the application thereof of IL-1 β and IL-17A |
JP6993228B2 (en) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor / anti-BACE1 multispecific antibody and usage |
JP6859259B2 (en) | 2014-11-19 | 2021-04-14 | ジェネンテック, インコーポレイテッド | Antibodies to BACEl and its use for neurological disease immunotherapy |
JP2021501752A (en) | 2017-11-02 | 2021-01-21 | ノバルティス アーゲー | How to treat tendon disorders with interleukin-17 (IL-17) antagonists |
WO2023091609A2 (en) * | 2021-11-18 | 2023-05-25 | Twist Bioscience Corporation | Cytokine variant antibodies and methods of use |
WO2023223211A1 (en) | 2022-05-16 | 2023-11-23 | Novartis Ag | Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists |
WO2023223263A1 (en) | 2022-05-18 | 2023-11-23 | Novartis Ag | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056470A2 (en) * | 2005-11-08 | 2007-05-18 | Genentech, Inc. | Neuropilin antagonists |
WO2007106769A2 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
WO2007147019A2 (en) * | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
WO2008047134A2 (en) * | 2006-10-18 | 2008-04-24 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
WO2008100805A2 (en) * | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
WO2009136286A2 (en) * | 2008-05-05 | 2009-11-12 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
ATE135397T1 (en) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
ES2096590T3 (en) | 1989-06-29 | 1997-03-16 | Medarex Inc | BI-SPECIFIC REAGENTS FOR AIDS THERAPY. |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
DE4118120A1 (en) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
JP3312357B2 (en) | 1992-12-11 | 2002-08-05 | ザ ダウ ケミカル カンパニー | Multivalent single chain antibody |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US20020177188A1 (en) | 1998-05-15 | 2002-11-28 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
ES2380812T3 (en) | 1999-12-23 | 2012-05-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
NZ544317A (en) | 2003-07-08 | 2009-05-31 | Genentech Inc | IL-17 A/F heterologous polypeptides and therapeutic uses thereof |
US7790163B2 (en) * | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
ATE530578T1 (en) | 2006-08-11 | 2011-11-15 | Schering Corp | ANTIBODIES TO IL-17A |
EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
WO2010034443A1 (en) | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
AR075998A1 (en) | 2009-04-01 | 2011-05-11 | Genentech Inc | TREATMENT OF INSULIN RESISTANT DISORDERS. PHARMACEUTICAL COMPOSITION. USE. KIT |
RU2605318C2 (en) | 2009-05-05 | 2016-12-20 | Новиммун С.А. | Anti-il-17f antibodies and methods for use thereof |
-
2009
- 2009-08-26 US US12/547,728 patent/US8790642B2/en active Active
- 2009-08-28 CN CN2013102735648A patent/CN103360493A/en active Pending
- 2009-08-28 TW TW098129172A patent/TW201012478A/en unknown
- 2009-08-28 AR ARP090103325A patent/AR073232A1/en unknown
- 2009-08-28 BR BRPI0916915A patent/BRPI0916915A2/en not_active IP Right Cessation
- 2009-08-28 EP EP09792076A patent/EP2321349A2/en not_active Withdrawn
- 2009-08-28 WO PCT/US2009/055420 patent/WO2010025400A2/en active Application Filing
- 2009-08-28 KR KR1020117006871A patent/KR20110055692A/en not_active Application Discontinuation
- 2009-08-28 AU AU2009285616A patent/AU2009285616B2/en not_active Ceased
- 2009-08-28 CA CA2732642A patent/CA2732642A1/en not_active Abandoned
- 2009-08-28 SG SG10201507009YA patent/SG10201507009YA/en unknown
- 2009-08-28 JP JP2011525247A patent/JP2012501186A/en active Pending
- 2009-08-28 EP EP17158636.5A patent/EP3211008A1/en not_active Withdrawn
- 2009-08-28 MX MX2011002073A patent/MX337684B/en active IP Right Grant
- 2009-08-28 CN CN2009801338455A patent/CN102137872A/en active Pending
- 2009-08-28 PE PE2011000189A patent/PE20110801A1/en not_active Application Discontinuation
-
2011
- 2011-01-28 ZA ZA2011/00749A patent/ZA201100749B/en unknown
- 2011-01-30 IL IL210942A patent/IL210942A0/en unknown
- 2011-02-24 CL CL2011000397A patent/CL2011000397A1/en unknown
-
2014
- 2014-01-06 US US14/148,414 patent/US9512217B2/en active Active
-
2015
- 2015-02-17 AU AU2015200790A patent/AU2015200790A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056470A2 (en) * | 2005-11-08 | 2007-05-18 | Genentech, Inc. | Neuropilin antagonists |
WO2007106769A2 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
WO2007147019A2 (en) * | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
WO2008047134A2 (en) * | 2006-10-18 | 2008-04-24 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
WO2008100805A2 (en) * | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
WO2009136286A2 (en) * | 2008-05-05 | 2009-11-12 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
Non-Patent Citations (1)
Title |
---|
WARK K L ET AL: "Latest technologies for the enhancement of antibody affinity" ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), pages 657-670, XP024892147 ISSN: 0169-409X [retrieved on 2006-08-07] * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1641822B1 (en) * | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
US10011654B2 (en) | 2003-07-08 | 2018-07-03 | Genentech, Inc. | Antibodies directed to IL-17A/IL-17F heterodimers |
US9650437B2 (en) | 2008-05-05 | 2017-05-16 | Novimmune S.A. | Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies |
US9475873B2 (en) | 2009-05-05 | 2016-10-25 | Novimmune Sa | Nucleic acids encoding anti-IL-17F antibodies and methods of use thereof |
US10808032B2 (en) | 2010-05-20 | 2020-10-20 | Ablynx Nv | Biological materials related to HER3 |
US9932403B2 (en) | 2010-05-20 | 2018-04-03 | Ablynx Nv | Biological materials related to HER3 |
EP3534159A1 (en) | 2011-01-07 | 2019-09-04 | UCB Biopharma SPRL | Lipocalin 2 as a biomarker for il-17 inhibitor therapy efficacy |
US11466324B2 (en) | 2011-01-07 | 2022-10-11 | UCB Biopharma SRL | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
WO2012093254A1 (en) | 2011-01-07 | 2012-07-12 | Ucb Pharma S.A. | Lipocalin 2 as a biomarker for il-17 inhibitor therapy efficacy |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
JP2014505474A (en) * | 2011-01-14 | 2014-03-06 | ユセベ ファルマ ソシエテ アノニム | Antibody molecules that bind to IL-17A and IL-17F |
US9034600B2 (en) | 2011-01-14 | 2015-05-19 | Ucb Biopharma Sprl | DNA encoding antibody molecules which bind IL-17A and IL-17F |
US8580265B2 (en) | 2011-01-14 | 2013-11-12 | Ucb Pharma S.A. | Antibody molecules which bind IL-17A and IL-17F |
US11919950B2 (en) | 2011-01-14 | 2024-03-05 | UCB Biopharma SRL | Expression vector encoding antibody molecule which binds IL-17A and IL-17F |
JP2017046699A (en) * | 2011-01-14 | 2017-03-09 | ユーシービー バイオファルマ エスピーアールエル | Antibody molecules that bind to il-17a and il-17f |
US9988446B2 (en) | 2011-01-14 | 2018-06-05 | Ucb Biopharma Sprl | Methods of treatment using antibodies which bind IL-17A and IL-17F |
WO2012095662A1 (en) | 2011-01-14 | 2012-07-19 | Ucb Pharma S.A. | Antibody molecules which bind il-17a and il-17f |
EP3219728A1 (en) | 2011-01-14 | 2017-09-20 | UCB Biopharma SPRL | Antibody molecules which bind il-17a and il-17f |
AU2012257942B2 (en) * | 2011-05-05 | 2015-08-20 | Merck Patent Gmbh | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same |
AU2012257942A8 (en) * | 2011-05-05 | 2015-09-10 | Merck Patent Gmbh | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same |
WO2012156219A1 (en) * | 2011-05-05 | 2012-11-22 | Ablynx Nv | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
US10017568B2 (en) | 2011-05-05 | 2018-07-10 | Merck Patent Gmbh | Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and method of treatment using same |
EP3363815A1 (en) * | 2011-05-05 | 2018-08-22 | Merck Patent GmbH | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
JP2018154628A (en) * | 2011-05-05 | 2018-10-04 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツングMerck Patent GmbH | Amino acid sequences for il-17a, il-17f and/or il17-a/f, and polypeptides comprising amino acid sequences |
US11773159B2 (en) | 2011-05-05 | 2023-10-03 | Merck Patent Gmbh | Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same |
EA035973B9 (en) * | 2011-05-05 | 2021-03-30 | Мерк Патент Гмбх | Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same |
EP4105231A1 (en) * | 2011-05-05 | 2022-12-21 | Merck Patent GmbH | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
KR20140132661A (en) * | 2011-05-05 | 2014-11-18 | 메르크 파텐트 게엠베하 | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
KR102083230B1 (en) | 2011-05-05 | 2020-03-02 | 메르크 파텐트 게엠베하 | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
CN103717618A (en) * | 2011-05-05 | 2014-04-09 | 默克专利股份有限公司 | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
EA035973B1 (en) * | 2011-05-05 | 2020-09-08 | Мерк Патент Гмбх | Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same |
JP2014516945A (en) * | 2011-05-05 | 2014-07-17 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Amino acid sequence for IL-17A, IL-17F and / or IL17-A / F and a polypeptide comprising said amino acid sequence |
US10829552B2 (en) | 2011-05-05 | 2020-11-10 | Merck Patent Gmbh | Polypeptides that bind to IL-17A, IL-17F and/or IL17-A/F and methods of treatment using same |
JP2020193195A (en) * | 2011-05-05 | 2020-12-03 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツングMerck Patent GmbH | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
US10208113B2 (en) | 2014-06-23 | 2019-02-19 | Janssen Biotech, Inc. | Interferon α and ω antibody antagonists |
US10759854B2 (en) | 2014-06-23 | 2020-09-01 | Janssen Biotech, Inc. | Interferon alpha and omega antibody antagonists |
US10358491B2 (en) | 2014-06-23 | 2019-07-23 | Janssen Biotech, Inc. | Interferon alpha and omega antibody antagonists |
WO2016070062A3 (en) * | 2014-10-31 | 2016-08-18 | Genentech, Inc. | Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same |
US11492396B2 (en) | 2015-10-27 | 2022-11-08 | UCB Biopharma SRL | Methods of treatment using anti-IL-17A/F antibodies |
WO2017072183A1 (en) * | 2015-10-27 | 2017-05-04 | Ucb Biopharma Sprl | Methods of treatment using anti-il-17a/f antibodies |
Also Published As
Publication number | Publication date |
---|---|
US9512217B2 (en) | 2016-12-06 |
IL210942A0 (en) | 2011-04-28 |
CL2011000397A1 (en) | 2012-03-30 |
US20140314763A1 (en) | 2014-10-23 |
US8790642B2 (en) | 2014-07-29 |
AU2009285616A1 (en) | 2010-03-04 |
MX337684B (en) | 2016-03-15 |
CN102137872A (en) | 2011-07-27 |
PE20110801A1 (en) | 2011-10-31 |
EP2321349A2 (en) | 2011-05-18 |
CN103360493A (en) | 2013-10-23 |
AR073232A1 (en) | 2010-10-20 |
EP3211008A1 (en) | 2017-08-30 |
SG10201507009YA (en) | 2015-10-29 |
BRPI0916915A2 (en) | 2015-11-24 |
AU2009285616B2 (en) | 2014-11-20 |
US20100055103A1 (en) | 2010-03-04 |
ZA201100749B (en) | 2012-04-25 |
MX2011002073A (en) | 2011-03-29 |
KR20110055692A (en) | 2011-05-25 |
AU2015200790A1 (en) | 2015-03-05 |
CA2732642A1 (en) | 2010-03-04 |
TW201012478A (en) | 2010-04-01 |
WO2010025400A3 (en) | 2010-07-15 |
JP2012501186A (en) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9512217B2 (en) | Antibodies binding to IL-17A | |
JP5766179B2 (en) | Compositions and methods for increasing muscle growth | |
JP3957765B2 (en) | Anti-VEGF antibody | |
AU2005333602B2 (en) | High affinity antibodies against HMGB1 and methods of use thereof | |
AU2008243049B2 (en) | Novel compounds | |
DK2364729T6 (en) | IL-17 antagonistic antibodies | |
JP2020036611A (en) | Humanized antibodies | |
JP2018140992A (en) | Ultralong complementarity determining regions and uses thereof | |
JP2022137092A (en) | Composition of therapeutic low-density lipoprotein-associated protein 6 (lrp6) antibody, and method for using the same | |
CN109929035B (en) | Anti-human NGF antibody and preparation method and application thereof | |
AU2019324403A1 (en) | Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof | |
TW202237651A (en) | Novel conjugate molecules targeting cd39 and tgfβeta | |
CN114286827B (en) | Humanized anti-IL 17A antibodies and uses thereof | |
WO2022262496A1 (en) | Immunoconjugate molecules and related methods and compositions thereof | |
WO2023050826A1 (en) | Immunoconjugates containing tnf-alpha and related methods and compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980133845.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09792076 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009285616 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2732642 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2009792076 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009792076 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009285616 Country of ref document: AU Date of ref document: 20090828 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000189-2011 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011000397 Country of ref document: CL Ref document number: MX/A/2011/002073 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011500414 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2011525247 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1381/CHENP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20117006871 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011111436 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0916915 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110222 |